DVAX Company Profile and Key Details

Q: Who are the executives of DVAX?

Ms. Meg SmithVice President Sales & OperationsNicole ArndtSenior Mang. of Investor RelationsDr. Robert JanssenChief Medical Officer and Senior Vice President of Clinical Devel., Medical & Regulatory AffairsMs. Cecilia VitugVice President of HRMr. Paul CoxVice President of Investor Relations & Corporation CommunicationsMs. Kelly MacDonaldSenior Vice President & Chief Financial OfficerMr. Ryan SpencerChief Executive Officer & DirectorMr. David F. NovackPres & Chief Operating OfficerMr. Justin BurgessPrincipal Accounting Officer & ControllerMr. John SlebirSenior Vice President & Gen. CounselMr. Michael S. OstrachAdvisorMr. Jeff P. CoonCHRO and Senior Vice President of HR & Admin.Mr. Donn CasaleChief Commercial Officer

NASDAQ : DVAX

Dynavax Technologies

$15.50

At Close 4:00 PM

Not Actively Trading

61.88

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Dynavax Technologies Corporation (DVAX) stock remained unchanged at $15.50 a share on NASDAQ. The stock opened at $15.50, fluctuating between $15.50 to $15.50 during the session.

Stock Snapshot

15.5

Prev. Close

1.82B

Market Cap

15.5

Day Low

-41.891891891891895

P/E Ratio

-0.37

EPS (TTM)

0.75

Cash Flow per Share

15.5

Open

117.42M

Number of Shares

15.5

Day High

86.1%

Free Float in %

4.81

Book Value

5.66M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 10, 2026	15.50	15.50	15.50	15.50	5.66M
Feb 09, 2026	15.49	15.50	15.49	15.50	7.11M
Feb 06, 2026	15.49	15.50	15.49	15.50	2.01M
Feb 05, 2026	15.50	15.50	15.49	15.49	3.63M
Feb 04, 2026	15.48	15.59	15.47	15.51	4.35M
Feb 03, 2026	15.46	15.49	15.46	15.48	3.43M
Feb 02, 2026	15.48	15.50	15.48	15.49	822.66K
Jan 30, 2026	15.48	15.50	15.47	15.49	1.56M
Jan 29, 2026	15.49	15.50	15.48	15.48	894.35K
Jan 28, 2026	15.50	15.51	15.48	15.48	2.25M
Jan 27, 2026	15.49	15.55	15.47	15.48	1.47M
Jan 26, 2026	15.51	15.56	15.49	15.52	1.77M
Jan 23, 2026	15.64	15.65	15.51	15.51	2.18M
Jan 22, 2026	15.68	15.69	15.65	15.65	1.84M
Jan 21, 2026	15.56	15.69	15.56	15.68	1.62M
Jan 20, 2026	15.63	15.69	15.61	15.68	2.45M
Jan 16, 2026	15.65	15.67	15.60	15.63	1.83M
Jan 15, 2026	15.59	15.67	15.59	15.62	2.43M
Jan 14, 2026	15.69	15.69	15.57	15.60	2.2M
Jan 13, 2026	15.68	15.72	15.66	15.72	2.97M

Contact Details

EmeryVille, CA 94608

United States

https://www.dynavax.com 510 848 5100

About Company

Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 LNTH

-0.31-0.31%

Lantheus Holdings, Inc.$100.39 ANIP

0.76+1.07%

ANI Pharmaceuticals, Inc.$71.46 ETON

-0.95-1.61%

Eton Pharmaceuticals, Inc.$57.88 ALKS

0.71+1.56%

Alkermes plc$46.11 SUPN

-0.38-0.90%

Supernus Pharmaceuticals, Inc.$41.69 HROW

-0.97-2.58%

Harrow Health, Inc.$36.58 PAHC

-0.22-0.60%

Phibro Animal Health Corporation$36.58 INDV

-0.26-0.75%

Indivior Pharmaceuticals Inc$34.51 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98

Frequently Asked Questions

What is the current Dynavax Technologies Corporation (DVAX) stock price?

Dynavax Technologies Corporation (NASDAQ: DVAX) stock price is $15.50 in the last trading session. During the trading session, DVAX stock reached the peak price of $15.50 while $15.50 was the lowest point it dropped to. The percentage change in DVAX stock occurred in the recent session was 0% while the dollar amount for the price change in DVAX stock was $0.00.

DVAX's industry and sector of operation?

The NASDAQ listed DVAX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Dynavax Technologies Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DVAX?

Ms. Meg Smith
Vice President Sales & Operations
Nicole Arndt
Senior Mang. of Investor Relations
Dr. Robert Janssen
Chief Medical Officer and Senior Vice President of Clinical Devel., Medical & Regulatory Affairs
Ms. Cecilia Vitug
Vice President of HR
Mr. Paul Cox
Vice President of Investor Relations & Corporation Communications
Ms. Kelly MacDonald
Senior Vice President & Chief Financial Officer
Mr. Ryan Spencer
Chief Executive Officer & Director
Mr. David F. Novack
Pres & Chief Operating Officer
Mr. Justin Burgess
Principal Accounting Officer & Controller
Mr. John Slebir
Senior Vice President & Gen. Counsel
Mr. Michael S. Ostrach
Advisor
Mr. Jeff P. Coon
CHRO and Senior Vice President of HR & Admin.
Mr. Donn Casale
Chief Commercial Officer

How DVAX did perform over past 52-week?

DVAX's closing price is 68.48% higher than its 52-week low of $9.20 where as its distance from 52-week high of $15.73 is -1.46%.

How many employees does DVAX have?

Number of DVAX employees currently stands at 405.

Link for DVAX official website?

Official Website of DVAX is: https://www.dynavax.com

How do I contact DVAX?

DVAX could be contacted at phone 510 848 5100 and can also be accessed through its website. DVAX operates from 2100 Powell Street, EmeryVille, CA 94608, United States.

How many shares of DVAX are traded daily?

DVAX stock volume for the day was 5.66M shares. The average number of DVAX shares traded daily for last 3 months was 3.16M.

What is the market cap of DVAX currently?

The market value of DVAX currently stands at $1.82B with its latest stock price at $15.50 and 117.42M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	405
Beta	0.93
Sales or Revenue	$232.28M
5Y Sales Change%	12.726%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Employees	405
Beta	0.93
Sales or Revenue	$232.28M
5Y Sales Change%	12.726%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

DVAX Company Profile and Key Details

Dynavax Technologies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook